User Fees Should Be Pared Of Costly Administrative Provisions – CDRH
This article was originally published in The Gray Sheet
Device user fee implementation should not be cluttered with provisions that would diminish the cost utility of the program, CDRH Director David Feigal is cautioning
You may also be interested in...
FDA device user fee legislation developed by the Clinton Administration and recently submitted in draft form to Congress is "dormant" but not yet dead, officials in the Office of Management and Budget say.
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.